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Abstract: We report on the screening of ethanolic extracts from 33 deep-sea Antarctic 
marine sponges for different biological activities. We monitored hemolysis, inhibition of 
acetylcholinesterase,  cytotoxicity  towards  normal  and  transformed  cells  and  growth 
inhibition of laboratory, commensal and clinically and ecologically relevant bacteria. The 
most prominent activities were associated with the extracts from sponges belonging to the 
genus Latrunculia, which show all of these activities. While most of these activities are 
associated to already known secondary metabolites, the extremely strong acetylcholinesterase 
inhibitory  potential  appears  to  be  related  to  a  compound  unknown  to  date.  Extracts  
from  Tetilla  leptoderma,  Bathydorus  cf.  spinosus,  Xestospongia  sp.,  Rossella  sp.,  
Rossella cf. racovitzae and Halichondria osculum were hemolytic, with the last two also 
showing moderate cytotoxic potential. The antibacterial tests showed significantly greater 
activities of the extracts of these Antarctic sponges towards ecologically relevant bacteria 
from sea water and from Arctic ice. This indicates their ecological relevance for inhibition of 
bacterial microfouling.  
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1. Introduction 
The marine environment covers around 70% of the Earth surface and has extremely high biodiversity. 
It is also a rich source of natural compounds that have previously unrecognized chemical structures and 
biological activities. Since 1974, when the first sponge-derived natural products become part of the 
pharmacopeia (e.g., cytarabine [Ara-C] and vidarabine [Ara-A]), marine natural products have gained 
much research interest [1,2]. So far, over 20,000 natural products have been isolated and identified from 
various marine organisms [3], and about a dozen natural marine-derived compounds and their analogs or 
derivatives are currently in different phases of clinical trials [1,2].  
However, research and isolation of these compounds has been mainly directed towards organisms 
from temperate and tropical seas. Although the polar marine regions comprise a large portion of the total 
ocean area of the world, with Antarctica alone representing 10%, the difficulties associated with access 
to these regions has meant that only 3% of the marine natural products described today are derived from 
polar environments [4,5]. The harsh environmental conditions in the polar regions have for a long time 
been considered to have negative effects on biodiversity, interspecies competition and the incidence of 
chemical defense in polar marine organisms [4]. However, it was shown recently that the biodiversity in 
these areas can be compared to that in temperate and tropical regions, which applies especially to the 
marine sponges [4,6].  
Sponges are sessile marine feeders and are the predominant species of the Antarctic benthos [7]. They 
have developed many adaptations that have allowed them to survive in cold waters, like the production 
of ―antifreeze‖ peptides [8] and their ability to exploit additional nutrient resources [6]. Moreover, 
Antarctic sponges represent the main prey of various predators, like sea stars and nudibranchs, and they 
provide a habitat for associated fauna, which range from microorganisms, like bacteria and diatoms, to 
larger invertebrates, like crustaceans, bivalves and polychaetes [6,9,10]. It is therefore not surprising that 
marine sponges from polar environments have developed a collection of chemical defense mechanisms 
that are used as repellents and in territorial competition. For instance, a large number of organohalogens 
have been detected in Antarctic sponges, which might be released into the seawater by the producers and 
which eventually enter the food web, since some of these compounds were also discovered in marine 
mammals [11]. 
In general, sponge research is yielding more than 200 new pharmacologically active metabolites per 
year  at  present,  and  several  compounds  that  are  derived  from  sponges  or  from  sponge-associated 
bacteria are in different phases of clinical trials. To shed some light on pharmacologically interesting 
novel compounds from polar environments in the present study, we report the screening results for 
hemolytic, anti-acetylcholinesterase (AChE) and cytotoxic activities detected in ethanolic extracts from 
33 Antarctic marine sponge species. The extracts were also assayed against a broad range of laboratory, 
commensal and clinically relevant bacterial strains, and their potential ecological role was assessed by Mar. Drugs 2013, 11  1128 
 
 
testing their inhibitory potential on ecologically relevant bacteria isolated from marine waters and from 
Arctic ice. 
2. Results and Discussion 
In contrast to our previous study on aqueous and organic extracts from tropical marine sponges, 
where we described at least one potent biological activity in each of the tested extract [12], ethanolic 
extracts from the Antarctic sponge species tested in the present study did not show such a wide spectrum 
of bioactivities. The sponge genus that showed the broadest spectrum and highest activities here was 
Latrunculia (i.e., extracts #37/L and #46). This sponge genus is known to produce numerous bioactive 
natural products, such as, for example, the cytotoxic discorhabdins [13,14] and the 2-thiazolidinone 
macrolides known as the latrunculins, which can disrupt microfilament organization [15]. 
Hemolytic activity was associated with only ten of the sponge samples and was most prominent in the 
extract of the sponge Latrunculia cf. bocagei (#46) (Table 1). However, it is interesting to note that the 
sponge extract from Latrunculia cf. lendenfeldi (#37/L) did not show any hemolytic activity. Although 
lower than the activity seen for extract #46, high hemolytic activity was detected in the extracts from 
Bathydorus cf. spinosus (#8), Halichondria osculum (#45h), Xestospongia sp. (#48/1), Rossella cf. 
racovitzae (#167), Tetilla leptoderma (#55), and from a sponge of the family of Microcionidae (#41). No 
previous data on hemolytic activities of the marine sponge extracts used in this study have been reported 
to date. In comparison, in our previous study on the biological activities of extracts from tropical marine 
sponges [12], hemolytic activity was present in about half of the organic extracts tested.  
AChE inhibitors are compounds that have potential use in treating disorders like Alzheimer disease, 
myasthenia gravis and glaucoma [16]. In the present study, AChE inhibitory activities were observed in 
two extracts only, which were from sponges of the same genus: Latrunculia cf. lendenfeldi (#37/L) and 
Latrunculia cf. bocagei (#46), (Table 1). The AChE-inhibitory potential in these extracts was extremely 
high; indeed, 50% of the enzyme activity could be inhibited by only few ng/mL, which indicates that the 
isolated active substance should probably act in the range of picograms. A hexane extract from the Red 
Sea Latrunculia magnifica was reported to contain a partly characterized compound that can induce 
inhibition of butyrylcholinesterase [17], although, to the best of our knowledge, the exact chemical 
structure of this active component was never determined. The observed AChE-inhibitory potential of 
Latrunculia extracts in our study is however not linked to latrunculins, biologically active secondary 
metabolites present in this sponge genus [15], since in the control experiment, latrunculin A (up to the 
concentration of 5 μg/mL) failed to inhibit AChE. Due to the very low amounts of any such active 
compound(s) in the extracts from L. cf. lendenfeldi (#37/L) and L. cf. bocagei (#46) that are needed for 
the inhibition of AChE, isolation of the active compound(s) from this sponge genus appears to be worth 
further study.  
   Mar. Drugs 2013, 11  1129 
 
 
Table 1. Hemolytic, anti-acetylcholinesterase and cytotoxic activities of the most active 
sponge extracts. Empty spaces in columns denote that the tested sponge extract exhibited no 
hemolytic or anti-acetylcholinesterase (AChE) activity. 
Sponge Species  S#  Hemolytic Activity 
1  Anti-AChE Activity 
2  Cytotoxic Activity 
3 
        V-79 cells  CaCo-2 cells 
Bathydorus cf. spinosus  8  0.045    95.2 ±  7.7  91.8 ±  10.9 
Unidentified sponge 1  10  0.014    97.6 ±  8.5  85.7 ±  8.1 ** 
Cinachyra cf. barbata  27  0.008    97.9 ±  11.2  95.0 ±  8.9 
Rossella sp.  34  0.0025    101.1 ±  12.9  100.0 ±  10.0 
Latrunculia cf. lendenfeldi  37/L    1.3  0  2.1 ±  1.6 
Microcionidae spp.  41  0.017    102.8 ±  9.9  102.3 ±  11.2 
Halichondria osculum  45h  0.025    62.9 ±  11.9  56.6 ±  6.7 * 
Latrunculia cf. bocagei  46  0.15  9  0  0 
Xestospongia sp.  48/1  0.015    89.0 ±  8.7  95.2 ±  11.7 
Isodictya toxophila  51      84.7 ±  10.4  97.7 ±  8.9 ** 
Tetilla leptoderma  55  0.014    91.9 ±  11.4  96.7 ±  11.1 
Demospongia sp.  124      102.2 ±  12.2  96.2 ±  11.0 
Rossella cf. racovitzae  167  0.012    55.7 ±  11.9  93.5 ±  7.5 ** 
S#, sponge extract code; 
1 expressed as 1/t50 (min
−1) at 400 μg dried extract/mL in the assay; 
2 expressed as concentration 
of the dried extract (ng/mL) that resulted in 50% inhibition of the enzyme activity; 
3 viability of V-79 and CaCo-2 cell 
lines treated with 100 μg/mL of the dried extract, expressed as % of control; significant difference in cytotoxic activity 
between V-79 and CaCo-2 cell lines (* p < 0.05; ** p < 0.01). 
The discovery of new antibiotics is one of the most important goals in biomedical research, as the 
appearance of multiresistant bacterial strains has made certain human and animal infections virtually 
untreatable. Sponges are known to contain a high number of compounds that act against terrestrial 
pathogenic bacteria, while considerably lower activities have been observed against marine bacteria [18]. 
Furthermore, in comparison with sponges found in temperate and tropical seas, Antarctic sponges have 
been reported to have a smaller number of antimicrobial secondary metabolites [19] that show generally 
weaker activities [20]. Previous screenings of crude extracts from 93 Arctic sponges against bacteria and 
fungi associated with opportunistic infections showed that about 10% of the sponges yielded significant 
antimicrobial activities, with IC50 values from 0.2 to 5 μg/mL [5]. In the present study, only eight 
ethanolic  extracts  from  Antarctic  sponges  showed  antimicrobial  activities  against  laboratory, 
commensal  and  pathogenic  bacteria  (Table  2).  The  extracts  from  Halichondria  osculum  (#45h), 
Hemigellius bidens (#41a), Latrunculia cf. lendenfeldi (#37/L) and the sponge Rossella sp. (#4) were 
active against the majority of the bacterial strains tested, with a clear specificity towards Gram-positive 
bacteria. The highest activity and thus lowest MIC, was seen for the L. cf. lendenfeldi (#37/L) extract; 
e.g., its MIC for inhibition of Staphylococcus aureus (MRSA) S-943 was only 15 μg/mL. This sponge 
extract, albeit at approximately five-fold to 50-fold higher concentrations, also showed the greatest 
efficacy  for  the  inhibition  of  the  growth  of  Gram-negative  bacteria,  as  mainly  seen  against  the 
Escherichia coli strains. The activities of the remaining four sponge extracts (unidentified Demosponge 
[#38], Isodictya setifera [#58], Myxilla [#26] and Haliclona flagellifera [#40a]) were generally lower 
and seen only towards a few bacterial strains. Mar. Drugs 2013, 11  1130 
 
 
Table 2. Antibacterial activities (MICs) of the sponge extracts against the laboratory, commensal and clinically relevant bacterial strains. 
Empty spaces in columns denote that the tested sponge extract exhibited no antibacterial activity. 
Bacterial Strain  Sponge Extract MIC (μg/mL) 
 
Latrunculia cf. 
lendenfeldi (#37L) 
Demosponge 
(#38) 
Halichondria 
osculum (#45h) 
Isodictya 
setifera (#58) 
Hemigellius 
bidens (#41a) 
Rossella 
sp. (#4) 
Myxilla 
sp. (#26) 
Haliclona (Gellius) 
flagellifera (#40a) 
Staphylococcus aureus (MRSA) S-943 
A  15    200  600  400  350     
S. pseudintermedius (MRSP) S-053 
A  80    200    400       
S. pseudintermedius (MRSP) S-043 
A  80  50  200    400  30     
Listeria monocytogenes  90    250    500       
Staphylococcus epidermidis EXB-V55  100  150  250  200  80  300     
Staphylococcus aureus 10F  100    250    400  300     
Bacillus subtilis EXB-V68  8    2.5    80  30  60  65 
Macrococcus 1F  10  7  4  100  6  200  400  650 
Micrococcus 2F  70    25  150  60  150     
Escherichia coli HB101  700    250    400       
Escherichia coli EXB-V1  700        400       
ESBL-E. coli 206 (CTX-M-1; ST131) 
A  750               
ESBL-E. coli 192 (CTX-M-9; ST131) 
A  750               
ESBL-E. coli MS 30 (CTX-M-2) 
A  700        500       
Acinetobacter 1C  70  400  250           
KPC-Klebsiella pneumonia 
A                 
Enterobacter EXB-V11                 
Pseudomonas aeruginosa EXB-V28                 
Pseudomonas aeruginosa 06131 
A  700        400       
Pseudomonas aeruginosa 8591 
A                 
A multiresistant isolate. 
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Our data are generally in line with those obtained by McClintock and Gauthier [20], who screened 
non-polar extracts of 17 Antarctic sponges for inhibitory activities against bacteria and fungi. They 
showed  particularly  strong  inhibitory  activities  associated  with  extracts  from  the  sponge  species 
belonging  to  the  genera  Latrunculia  and  Haliclona.  The  antibacterial  activity  of  the  extract  from  
L. cf. lendenfeldi might be related to the presence of Latrunculia-associated natural products that have 
already been reported to have inhibitory potential against various Gram-positive and Gram-negative 
bacteria, which are known as the discorhabdins [21–23] and trunculins [24]. Furthermore, sponges of the 
genus Haliclona, which also include polar species, are known to contain antibacterial 3-alkylpyridinium 
alkaloids [25,26]. Similarly, sesquiterpenoids halichonadins [27] and a galactoside-specific lectin [28] 
from Halichondria sponges have been described to have antibacterial and antifungal effects, while 
extracts from sponges of the genus Hemigellius have not yet been reported to show any antibiotic 
properties. However, the present study shows antibacterial activities of  Hemigellius bidens extract 
against  all  of  the  tested  Gram-positive  bacterial  strains  and  also  against  a  clinical  multiresistant 
Pseudomonas  aeruginosa  isolate.  Furthermore,  the  same  extract  inhibited  the  growth  of  E.  coli 
laboratory  strains  and,  to  a  lesser  extent,  of  an  extended-spectrum  β-lactamase  (ESBL)-producing 
clinical isolate, although it was ineffective against the pandemic, virulent and multiresistant E. coli 
ST131 isolate. These data should be borne in mind when screening tests are performed using strains that 
are  solely  from  nonclinical  environments.  Weak  antimicrobial  activities  of  extracts  from  sponges 
belonging to the Antarctic genera of Isodictya have also been reported [20,29]. Moreover, a P. aeruginosa 
strain that is associated with this sponge was shown to have alkaloids that can inhibit the growth of 
Gram-positive bacteria [30]. Antimicrobial substances that have been derived from sponge-associated 
bacteria have also been reported for several other sponge species [18], and these might be responsible in 
part for the observed antimicrobial activities. Screening of methanolic extracts of Myxilla arenaria from 
the Indian Ocean did not reveal any activity against pathogenic bacteria and fungi [31]. To the best of our 
knowledge, there are no other reports on antibacterial activities of this sponge genus.  
Further analyses of the antibacterial potential of the Antarctic sponge extracts in the present study 
revealed significantly higher activities against Gram-negative bacterial strains isolated from sea water 
and from Arctic ice (Table 3). All of the already mentioned antibacterial sponge extracts inhibited the 
growth of these marine bacteria, with the most sensitive species being Pseudoalteromonas sp. Again, as 
in the case of pathogenic bacteria, the lowest minimal inhibitory concentration (MIC) values against the 
majority of the strains tested were observed for the Latrunculia cf. lendenfeldi (#37/L) extract. The 
growth of Pseudoalteromonas sp. was moderately inhibited also by other sponge extracts, as mainly 
those from Cinachyra cf. barbata (#27), Rossella sp. (#34), and Homaxinella cf. balfouriensis (#52). 
Janthinobacterium svalbardensis, a bacterial strain isolated from Arctic ice, was also highly susceptible 
to the L. cf. lendenfeldi (#37/L) extract, with a MIC of 90 ng/mL. It is interesting to note that all three 
Pseudomonas strains isolated from Arctic ice were resistant to all of the sponge extracts tested, which 
was also the case for most of the pathogenic strains of these bacteria (Table 1). The higher antibacterial 
potential of sponge extracts towards ecologically relevant bacteria probably reflects the sponge defense 
mechanisms that are designed to prevent bacterial colonization. A similar conclusion was reached also in 
a previous screening test of polar sponge extracts on sympatric bacterial strains isolated from seawater, 
sediment and stones [19]. Surprisingly, lipophilic and hydrophilic extracts from Antarctic sponges have 
shown only mild inhibitory activities against sponge-associated bacteria, which indicates that symbiotic Mar. Drugs 2013, 11  1132 
 
 
bacteria are probably not a common threat to sponges [29]; indeed, these symbiotic bacteria might 
instead be used as an alternative source of nutrients when these are scarce in the sponge environment [6].  
Compounds that show selective cytotoxic activities might be candidates for new chemotherapeutics, 
which is still the main focus of natural product chemists and pharmaceutical companies [18]. Currently, 
reports on cytotoxic metabolites from sponges that live in the polar regions are scarce. In the present 
study, the most prominent cytotoxicity was detected in the extracts of Latrunculia cf. lendenfeldi (#37/L) 
and Latrunculia cf. bocagei (#46) (Table 1). This is not surprising, knowing that this sponge genus has a 
variety of cytotoxic pyrroloiminoquinone alkaloids, the discorhabdins [13,14], that act on various tumor 
cell  lines.  Moderate  inhibition  of  cell  growth  was  observed  here  also  using  the  extracts  from 
Halichondria osculum (#45h) and Rossella cf. racovitzae (#167). Sponges of the genus Halichondria 
from temperate waters have been reported to contain cytotoxic depsipeptides [32] and steroids [33], as 
well as the halichondrins, polyether macrolides that show potent cell inhibitory activities at nanomolar 
concentrations [34,35]. Regarding the sponges of the genus Rossella, we were not able to retrieve any 
data on their cytotoxic potential. There were no distinctive selective cytotoxicities seen against the 
transformed cell lines used in the present study (CaCo-2 cells) with any of the sponge extracts tested, 
except  for  non-identified  sponge  1  (#10)  and  Halichondria  osculum  (#45h).  The  extracts  from  
Rossella cf. racovitzae and Isodictya toxophila were even significantly more active against the normal 
cell line.  
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Table 3. Antibacterial activities (minimal inhibitory concentrations (MICs)) of the sponge extracts against the environmental bacterial strains. 
Empty spaces in columns denote that the tested sponge extract exhibited no antibacterial activity. 
Bacterial Strain  Sponge Extract MIC (μg/mL) 
 
Latrunculia cf. 
lendenfeldi (#37L) 
Demosponge 
(#38) 
Halichondria 
osculum (#45h) 
Isodictya 
setifera (#58) 
Hemigellius 
bidens (#41a) 
Rossella sp. 
(#4) 
Myxilla sp. 
(#26) 
Haliclona (Gellius) 
flagellifera (#40a) 
Exignuobacterium sp. *  1.8  100  80  70  120  95  110  70 
Pseudoalteromonas sp. *  0.36  90  65    110  100  90  70 
Alteromonas sp. *  89.6  95  70    200  80  150   
Vibrio ruber *  0.9  70  85  65  120  90  90   
Janthinobacterium svalbardensis **  0.09  85  75    100  100  95  70 
Pseudomonas CR 13 **                 
Pseudomonas CR 14 **                 
Pseudomonas CR 285 **                 
* strains isolated from sea water; ** strains isolated from Arctic ice. 
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3. Experimental Section 
3.1. Sponge Collection 
Thirty-three sponge specimens that represented 28 species were collected in the Antarctic waters  
(60°  to 70°  S; 8°  to 61°  W) by bottom trawling and dredging at depths between 200 m and 900 m, during 
two cruises of the German Research Vessel ―Polarstern‖ in 2006/07 and 2008. The specimens were 
identified to at least the family level (Supplementary Table S1), and they were immediately frozen and 
kept at −20 ° C. The sponge samples were lyophilized prior to the extraction.  
3.2. Preparation of Extracts 
The weights of the lyophilized sponge samples were in the range of 0.52 g to 3.78 g. The lyophilized 
material was macerated and placed into labelled glass tubes, and 10 mL 96% ethanol (Merck, Germany) 
was added to each tube. The tubes were sealed with metal stoppers and parafilm and were shaken 
overnight (600 rpm) at 37 ° C. The extracts were then filtered, and the solvent was evaporated to the final 
volume of 1 mL. The dry weight of each sample was determined by drying an aliquot of a sample in a 
preweighed round-bottomed flask, with evaporation of the solvent under vacuum at 45 ° C. The dry 
weight was expressed in mg/mL of the 1 mL extract volumes prepared. Stock concentrations were in the 
range of 3.1 mg/mL to 10.3 mg/mL. The sponge species and the dry weights of the extracts are given in 
Supplementary Table S1.  
3.3. Hemolytic Activity Assay 
Fresh bovine erythrocytes were washed three times in physiological saline prior to use and then 
resuspended  in  erythrocyte  buffer  (130  mM  NaCl,  20  mM  TRIS-HCl,  pH  7.4).  The  erythrocyte 
suspension had an initial absorption at 650 nm of 1.0 ±  0.01 AU. The hemolytic activity was assayed 
using a microplate VIS absorption reader (Dynex, USA), as described previously [12]. With 100 μL of 
erythrocyte buffer in each microplate well, the ethanolic sponge extracts were added to each well at 
different final dry-extract concentrations, followed by 100 μL erythrocyte suspension. The volume of 
ethanol in the final reaction mixture did not exceed 20%, a concentration that was tested and shown not 
to be lytic. The time course of hemolysis was immediately started and monitored for 30 min. The 
hemolytic activity was expressed as the half-time of hemolysis (t50); e.g., the time in which the apparent 
absorbance at 650 nm dropped from 0.5 to 0.25. All of these measurements were carried out in triplicates 
at 25 ° C. The samples showing the highest hemolytic activities were further diluted with ethanol (1:10 
and 1:100) for confirmation of the hemolytic activities in further assays.  
3.4. Antibacterial Activity Assay 
The antibacterial activities of the sponge extracts were determined using the agar diffusion method,  
as  described  previously  [12].  A  broad  range  of  bacterial  strains  was  tested,  which  included  
ecologically relevant Gram-negative marine bacteria isolated from sea water (Exignuobacterium sp., 
Pseudoalteromonas sp., Alteromonas sp. and Vibrio ruber) and from Arctic ice (Janthinobacterium 
svalbardensis,  Pseudomonas  CR  13,  Pseudomonas  CR  14  and  Pseudomonas  CR  285).  These Mar. Drugs 2013, 11  1135 
 
 
antibacterial activities were also assayed against the following characterized strains of different origins: 
(1)  laboratory  strains:  E.  coli  HB101,  Bacillus  subtilis  EXB-V68,  Enterobacter  EXB-V11,  
P. aeruginosa EXB-V28 and Staphylococcus epidermidis EXB-V55; (2) commensal isolates from dog 
skin:  S.  aureus  10F,  Macrococcus  1F,  Micrococcus  2F  and  Acinetobacter  1C;  (3)  a  food  isolate:  
Listeria  monocytogenes;  and  (4)  clinical  isolates:  methicillin-resistant  S.  aureus  (MRSA)  S-943, 
methicillin-resistant  Staphylococcus  pseudintermedius  (MRSP)  S-053  and  S-043  ESBL-producing  
E.  coli  206  (CTX-M-1  group;  ST131),  ESBL-E.  coli  192  (CTX-M-9;  ST131),  ESBL-E.  coli  30 
(CTX-M-2),  carbapenemase  producing  (KPC)  Klebsiella  pneumoniae,  P.  aeruginosa  06131  and  
P. aeruginosa 8591. The strains were obtained from the EX (extremophilic microorganisms) and GM 
(genetic laboratory microbes) culture collections of the Chair of Molecular Genetics and Microbiology 
of the Biotechnical Faculty and of the Institute of Microbiology and Parasitology, Veterinary Faculty, 
University  of  Ljubljana,  Slovenia.  The  precultured  bacteria  (laboratory,  commensal  and  clinically 
relevant strains and strains isolated from Arctic ice) were grown in LB broth (Sigma, USA) and were 
used for the inoculation of Luria broth agar plates, to a final cell concentration of 5 ×  10
8/mL. Four holes 
of 1 cm in diameter were made in the agar of each agar plate, which were then filled with 100 μL of an 
ethanolic extract. Ethanol was tested for its antimicrobial activity (100 μL) as a control. The inhibition 
zone for each sample was determined after overnight incubation of the plates at 37 ° C. The plates 
containing the bacteria isolated from Arctic ice were incubated at 22 ° C. The extracts showing the 
highest inhibition of bacterial growth were further diluted with ethanol and used to determine the 
minimal inhibitory concentrations (MICs), which were defined as the lowest concentrations in μg/mL 
that inhibited the growth of tested microorganism 1 mm from the rim of the hole. All of the laboratory, 
commensal  and  clinical  bacterial  strains  were  also  assayed  with  standard  antibiotics  (tetracycline, 
kanamycin, rifampicin, ampicillin and chloramphenicol; Supplementary Table S2). The marine bacteria 
were precultured in liquid medium prepared by dissolving 5 g peptone and 1 g yeast extract in 1 L of 
aqueous solution of MgCl2· 6H2O (10 mM) and NaCl (300 mM). Agar plates containing this liquid 
medium were inoculated with the bacteria to a concentration of 5  ×   10
8/mL, and the antibacterial 
activities were tested as described above after an overnight incubation of the plates at 37 ° C. 
3.5. Acetylcholinesterase Inhibition Assay 
The AChE inhibition assay was performed according to the method of Ellman et al. [36]. AChE from 
electric eel (Sigma, USA) was dissolved in 100 mM phosphate buffer (pH 7.4) to a concentration of  
500 EU/mL. Prior to the assay, the enzyme was 100-fold diluted in the same buffer. With 100 μL Ellman 
reagent (5,5-dithiobis-2-nitrobenzoic acid) in 50 mM phosphate buffer (pH 7.4) containing the substrate 
acetylcholine (ACh) in 1 mM final concentration in each microplate well, 5 μL sponge extract and then 
45 μL AChE were added to start the reaction. Ethanol (5 μL) was used as a control. Ethanol-dissolved 
latrunculin A (5 μL, Molecular probes, USA) was also assayed for its AChE-inhibitory potential in final 
concentrations from 0.005 to 5 μg/mL. The time course of the enzymatic reaction was monitored over  
5 min at 405 nm and at 25 ° C. All the measurements were performed in triplicate. The extracts that 
showed  significant  AChE  inhibitory  activity  were  further  diluted  (1:10  and  1:100)  and  tested  for 
confirmation of the AChE inhibition activities in further assays. A VIS microplate reader (Dynex, USA) 
was used for these assays.  Mar. Drugs 2013, 11  1136 
 
 
3.6. Cytotoxic Activity 
In contrast to the previous biological tests, the cytotoxic activity was assayed only on selected sponge 
extracts, as those from: Bathydorus cf. spinosus (#8), non-identified sponge 1(#10), Cinachyra cf. barbata 
(#27),  Rossella  sp.  (#34),  Latrunculia  cf.  lendenfeldi  (#37/L),  Microcionidae  spp.  (#41),  
Halichondria osculum (#45h), Latrunculia cf. bocagei (#46), Xestospongia (#48/1), Isodictya toxophila 
(#51), Tetilla leptoderma (#55), Demospongiae (#124) and Rossella cf. racovitzae (#167). The cell lines 
used were: V-79-379 A (V-79) cells (diploid lung fibroblasts from Chinese hamster) and CaCo-2 cells 
(human colon adenocarcinoma). The V-79 cells were grown in advanced Eagle’s minimal essential 
medium (Gibco, Invitrogen, UK) and the CaCo-2 cells in advanced RPMI 1640 (Gibco), both at 37 ° C in 
a  CO2  incubator  (5%  CO2,  95%  air,  95%  relative  humidity).  Both  of  these  culture  media  were 
supplemented  with  2  mmol/L  L-glutamine  (Gibco),  100  U/mL  penicillin  (Gibco),  100  μg/mL 
streptomycin (Gibco) and 5% fetal bovine serum (Gibco). For the in vitro cytotoxicity assay, the cells 
were plated in 96-well microtiter plates (100 μL, Costar, USA) at a concentration of 5000 cells/well 
(V-79 cells) and 10,000 cells/well (CaCo-2 cells). After a 3-h incubation, the ethanol-dissolved extracts 
prepared in the respective media without serum were added, to a final concentration of 0.1 mg/mL, and 
the incubations were carried out for 1 h (under cell growth conditions). Ethanol (20 μL) was used as a 
control. The cells were then washed once with medium, and fresh medium with fetal bovine serum was 
added for a further 48 h (under cell growth conditions). The cytotoxicity was determined using the MTS 
(=3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)  test. 
To each well, 20 μL of MTS (CellTiter 96 AQueous Reagent, Promega, USA) was added to the cell 
culture. After 1 h, the absorbance at 490 nm was measured using a Bio-Tek microplate reader (Bio-Tek 
Instruments Inc., USA). The absorption corresponded to the amount of the soluble formazan product 
that  was  formed,  which  is  directly  proportional  to  the  number  of  viable  cells.  The  viability  was 
calculated as the ratio between absorbance at 490 nm of the treated and control cells, expressed as a 
percentage. The data are presented by means ±  SD of 3 independent experiments. The differences were 
analyzed using Student’s t-tests on two populations, with p < 0.05 and p < 0.01 considered significant. 
4. Conclusions  
The data from the present study are in line with previous reports on biological activities of polar 
marine sponges. Although the biological activities of these sponges are in generally associated with a 
lower number of species as compared to sponges from temperate and tropical regions, they are still 
widely unexplored and might provide valuable resources for new pharmaceutical lead compounds. One 
such example is seen with the extracts of the sponges of the genus Latrunculia, which were shown to 
contain an extremely potent inhibitor of AChE.  
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